	Adjusted hazard ratio (95% CI) (without dose)	Adjusted hazard ratio (95% CI) (with dose as time-dependent covariate)
Primary analysis		
Irbesartan (reference)	1.00	1.00
Telmisartan	0.85 (0.74 to 0.97)	0.85 (0.73 to 0.98)
Candesartan	0.99 (0.89 to 1.11)	1.01 (0.89 to1.15)
Losartan	0.93 (0.83 to 1.05)	0.96 (0.83 to 1.10)
Valsartan	0.86 (0.77 to 0.96)	0.88 (0.77 to 1.00)
Secondary analysis #1:		
Myocardial infarction		
Irbesartan (reference)	1.00	1.00
Telmisartan	0.92 (0.72 to 1.17)	0.99 (0.79 to 1.26)
Candesartan	1.01 (0.82 to 1.23)	1.00 (0.79 to 1.26)
Losartan	0.96 (0.78 to 1.20)	0.97 (0.76 to 1.26)
Valsartan	0.85 (0.70 to 1.04)	0.85 (0.68 to 1.07)
Secondary analysis #2:		
Stroke/TIA		
Irbesartan (reference)	1.00	1.00
Telmisartan	0.84 (0.66 to 1.08)	0.84 (0.64 to 1.10)
Candesartan	0.98 (0.80 to 1.20)	1.01 (0.79 to 1.27)
Losartan	0.90 (0.72 to 1.12)	0.93 (0.72 to 1.21)
Valsartan	0.90 (0.74 to 1.09)	0.93 (0.74 to 1.17)

Appendix 3 (as supplied by the authors): Primary and secondary analyses with and without adjustment for angiotensin receptor blocker dose

Appendix to: Antoniou T, Camacho X, Yao Z, et al. Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. *CMAJ* 2013; DOI:10.1503/cmaj.121771. Copyright © 2013 Canadian Medical Association or its licensors

Secondary analysis #3:		
Heart Failure		
Irbesartan (reference)	1.00	1.00
Telmisartan	0.80 (0.66 to 0.96)	0.78 (0.63 to 0.95)
Candesartan	1.02 (0.88 to 1.19)	1.09 (0.92 to 1.29)
Losartan	0.98 (0.84 to 1.15)	1.06 (0.88 to 1.28)
Valsartan	0.87 (0.75 to 1.01)	0.93 (0.78 to 1.10)
Secondary analysis #4: All		
cause-mortality		
Irbesartan (reference)	1.00	1.00
Telmisartan	0.95 (0.83 to 1.09)	0.93 (0.81 to 1.08)
Candesartan	1.05 (0.94 to 1.17)	1.06 (0.93 to 1.20)
Losartan	0.99 (0.87 to 1.11)	0.99 (0.86 to 1.14)
Valsartan	0.90 (0.80 to 1.00)	0.90 (0.79 to 1.03)